跳至主要内容
临床试验/JPRN-jRCTc030190081
JPRN-jRCTc030190081招募中1 期

Treatment with chemotherapy and dendritic cells pulsed with neoantigen-specific epitopes for pancreatic cancer. - PK-neoantigen-DCtest

Koido Shigeo0 个研究点目标入组 10 人开始时间: 2019年8月23日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 75age old(—)
性别
All

入选标准

  • Human leukocyte antigen (HLA)-A*02:01- or A*24:02-positive patients.
  • Patients with histologically or cytologically confirmed locally advanced or metastatic pancreatic cancer, or recurrent disease after surgery.
  • Patients with ages between 20 and 75 years.
  • Karnofsky performance status (KPS) of 80% to 100%.
  • Patients with a KPS of 70% were also included but only if KPS was decreased by poorly controlled cancerous pain at enrollment.
  • Patients had adequate hematologic, hepatic, and renal function.
  • Patients had a life expectancy of at least 3 months.
  • All patients provided written informed consent.

排除标准

  • The exclusion criteria were pregnancy, serious infections, severe underlying disease, severe allergic disease, and a judgment of unsuitability by the principal investigator.

研究者

发起方
Koido Shigeo

相似试验